Project Grant R01AI201635
Award Date 7/23/26
Completion Date 6/30/31
Dollars Obligated $688K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $182,391 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cell-painting strategies that enhance vaccine efficacy and immune activation through B cell targeting. The research develops amphiphile-protein conjugate vaccines that hitchhike on albumin to enter lymphoid tissues and activate germinal center responses, with the ability to...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $2,946,564 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to engineer immunocompetent human tissues and define inflammatory state transitions. The project develops tools to study chronic inflammation in complex human tissues by assembling immunocompetent microtissues derived from pluripotent stem cell progenitors in brain, liver, and adipose...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $380,000 on September 11, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop bespoke micellar nanoparticles for in vivo delivery of digital base editor treatments for primary immunodeficiency disease. The recipient will synthesize a novel uniform library of amphiphilic polymers and optimize micellar nanoparticles for binary base editor (guide RNA and...
- The National Institute of Allergy and Infectious Diseases awarded a cooperative agreement of $331,353 to the Regents of the University of Minnesota on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds a phase II/III platform trial investigating the efficacy and safety of immunomodulatory therapy for HIV-related cryptococcal meningitis. The research addresses the damage-response immune framework underlying the disease, moving beyond...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $2 million on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of cross-species virus infections and predict spillover events into human populations. The research exploits a novel resource called the "Fibroblast Zoo," a collection of primary dermal fibroblasts from 89 mammalian species, to determine host factors...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $423,500 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will generate and validate a series of TAM receptor tyrosine kinase (Tyro3, Axl, and Merkt) mutant mice designed to disentangle specific effector functions—phagocytosis of dead cells and anti-inflammatory signaling—rather than produce complete knockouts. By substituting...
- The National Institute of Allergy and Infectious Diseases awarded Hennepin Healthcare Research Institute $661,037 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate an interleukin-15 (IL-15) cytokine-based therapy intended to enhance T and B cell immune responses to Plasmodium parasites and improve malaria vaccine efficacy. The research uses novel peptide-MHC class II and B cell tetramers in experimental Plasmodium infection and vaccination...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota a $437,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 25, 2025, with completion targeted for May 31, 2027. This research initiative focuses on advancing gene therapy delivery for lung-specific diseases by evaluating adeno-associated virus (AAV) vector systems packaged within extracellular vesicles. The project...
- The National Institute of Allergy and Infectious Diseases awarded $407,326 to the Regents of the University of Minnesota on February 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the development, homeostasis, and specificity of HELIOS+ CD8+ T cells and their role in immune regulation. Research activities will establish model systems intended to dissect how these memory-phenotype CD8+ T cells, which express the transcription factor HELIOS,...
- The National Institute of Allergy and Infectious Diseases awarded The Regents Of The University Of Colorado (doing business as University Of Colorado-Denver) $153,680 on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research investigates the role of type 1 interferon signaling in promoting antigen archiving and vaccine stability within lymphatic endothelial cells. Lymphatic endothelial cells serve as the first point of contact for antigens and...